Holen Sie sich die Stockscreener-App
11.13
2.79%
-0.349
Schlusskurs vom Vortag:
$11.48
Offen:
$11.57
24-Stunden-Volumen:
157.13K
Relative Volume:
0.12
Marktkapitalisierung:
$1.08B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-137.25M
KGV:
-5.8894
EPS:
-1.89
Netto-Cashflow:
$-121.97M
1W Leistung:
-8.90%
1M Leistung:
-11.43%
6M Leistung:
+90.12%
1J Leistung:
+22.37%
1-Tages-Spanne:
$11.09
$11.57
1-Wochen-Bereich:
$11.09
$12.71
52-Wochen-Spanne:
$3.8951
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Firmenname
Oric Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 388-5600
Adresse
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Vergleichen Sie ORIC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
11.10 | 1.12B | 0 | -137.25M | -121.97M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.08 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.96 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.59 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
922.80 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
197.94 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-20 | Eingeleitet | Evercore ISI | Outperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2024-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-02-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-16 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Perform |
| 2022-04-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-03-25 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-03-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-19 | Eingeleitet | Citigroup | Neutral |
| 2020-05-19 | Eingeleitet | Guggenheim | Buy |
| 2020-05-19 | Eingeleitet | JP Morgan | Overweight |
| 2020-05-19 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Oric Pharmaceuticals Inc Aktie (ORIC) Neueste Nachrichten
Evercore ISI Group Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Outperform Recommendation - MSN
Oric Pharmaceuticals (ORIC) Upgraded to Buy: Here's What You Should Know - MSN
This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
ORIC Pharmaceuticals (ORIC) Initiates Coverage with Outperform Rating | ORIC Stock News - GuruFocus
Is ORIC Pharmaceuticals Inc. (4TZ) stock positioned for secular growthChart Signals & High Win Rate Trade Tips - newser.com
Why ORIC Pharmaceuticals Inc. (4TZ) stock attracts HNW investorsEarnings Risk Summary & Long-Term Safe Return Strategies - newser.com
Is ORIC Pharmaceuticals Inc. (4TZ) stock attractive for growth funds2025 Winners & Losers & Safe Entry Momentum Tips - newser.com
Can ORIC Pharmaceuticals Inc. stock resist sector downturnsJuly 2025 Drop Watch & Reliable Price Breakout Alerts - newser.com
Is ORIC Pharmaceuticals Inc. stock undervalued vs historical averagesEarnings Miss & Consistent Growth Stock Picks - newser.com
Why ORIC Pharmaceuticals Inc. (4TZ) stock benefits from AI revolutionQuarterly Market Summary & Risk Managed Investment Strategies - newser.com
Will ORIC Pharmaceuticals Inc. stock maintain momentum in 2025July 2025 Trends & Stepwise Trade Signal Guides - newser.com
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
ORIC: ORIC-944 demonstrates high ctDNA clearance and safety, supporting pivotal trials and market expansion - TradingView
Wolfe Research Initiates Coverage on Oric Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
Why institutional investors increase stakes in ORIC Pharmaceuticals Inc. (4TZ) stock2025 Risk Factors & Daily Profit Maximizing Tips - newser.com
The Technical Signals Behind (ORIC) That Institutions Follow - news.stocktradersdaily.com
Why ORIC Pharmaceuticals Inc. stock could see breakout soon2025 Technical Overview & Stock Portfolio Risk Management - newser.com
Is this a good reentry point in ORIC Pharmaceuticals Inc.2025 Historical Comparison & Stock Market Timing Techniques - newser.com
Analyst Initiation: Wolfe Research Rates ORIC Pharmaceuticals as 'Peer Perform' | ORIC Stock News - GuruFocus
JP Morgan Raises ORIC Pharmaceuticals (ORIC) Price Target to $20 - GuruFocus
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat
Can you recover from losses in ORIC Pharmaceuticals Inc.Weekly Volume Report & Entry and Exit Point Strategies - newser.com
Wolfe Research initiates coverage on ORIC Pharmaceuticals stock with Peerperform rating - Investing.com Canada
Citigroup Raises ORIC Pharmaceuticals Price Target to $16 | ORIC Stock News - GuruFocus
Relative strength of ORIC Pharmaceuticals Inc. in sector analysisJuly 2025 Market Mood & Target Return Focused Picks - newser.com
ORIC Pharma Surges Ahead With ORIC-944 And Enozertinib Data Momentum - RTTNews
Oric Pharmaceuticals' (ORIC) "Outperform" Rating Reaffirmed at Wedbush - MarketBeat
Why analysts recommend ORIC Pharmaceuticals Inc. (4TZ) stockWeekly Investment Recap & Free Growth Oriented Trading Recommendations - newser.com
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Oric Pharmaceuticals’ 2025 Restructuring: Potential Risks and Financial Implications - TipRanks
Wells Fargo & Company Lowers Oric Pharmaceuticals (NASDAQ:ORIC) Price Target to $19.00 - MarketBeat
Finanzdaten der Oric Pharmaceuticals Inc-Aktie (ORIC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oric Pharmaceuticals Inc-Aktie (ORIC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Oct 06 '25 |
Sale |
14.52 |
11,000 |
159,719 |
48,317 |
| Chacko Jacob | PRESIDENT AND CEO |
Oct 06 '25 |
Sale |
12.32 |
37,461 |
461,520 |
531,419 |
0.09%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):